Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17951102 | 1.00 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A | |
| SCHEMBL17951415 | 0.90 | MAPT (0.51) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A | |
| SCHEMBL10969723 | 0.81 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A | |
| SCHEMBL17951074 | 0.80 | MAPT (0.58) | ALDH1A1SMN1; SMN2KDM4ECYP2C19POLB | |
| SCHEMBL18710345 | 0.79 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A | |
| SCHEMBL153251 | 0.79 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A | |
| SCHEMBL12310224 | 0.79 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A | |
| SCHEMBL12885924 | 0.79 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A | |
| SCHEMBL5944062 | 0.78 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A | |
| SCHEMBL7296851 | 0.78 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2HTTKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304910-B2 | Janus kinase (JAK) family inhibitor, preparation of same, and applications thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| EP-3919494-B1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | JIANGSU VCARE PHARMATECH CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| EP-3919494-B1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | JIANGSU VCARE PHARMATECH CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-111518096-B | Janus kinase JAK family inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3919494-A1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | Jiangsu Vcare Pharmatech Co., Ltd (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-111518096-A | Janus kinase JAK family inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020156271-A1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | 江苏威凯尔医药科技有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JAK1, JAK3, JAK2 | ALDH1A1 1811/4885SMN1; SMN2 4714/4885HTT 3952/4885 |
| US-12304910-B2 | Janus kinase (JAK) family inhibitor, preparation of same, and applications thereof | JAK1, JAK3, JAK2 | ALDH1A1 1811/4885SMN1; SMN2 4714/4885HTT 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.